Did You Know...
...that "patent leather" got its name because the process of applying the polished black finish to leather was once patented?
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8105613 | Vaccine formulation Spore coat-associated proteins from members of Bacillus genera, and in particular spore-coat associated protein N (CotN), have utilization as adjuvants in vaccine formulations. The vaccine formulations most likely contain a virulence factor of bacterial origi... | 01/31/2012 |
| 8092810 | Use of polypeptides having antimicrobial activity The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for ... | 01/10/2012 |
| 8039006 | Solid composition containing bacillus-type non-pathogenic bacterial spores The invention relates to a composition of spores of nonpathogenic bacteria of the Bacillus genus, adsorbed onto a matrix made up of at least one water-insoluble adsorbent compound and a cellulose derivative, which can be obtained by the fluidized air bed tech... | 10/18/2011 |
| 7910115 | Polypeptide absorbable into digestive organs A polypeptide absorbable into digestive organs, which is linked with a bioactive polypeptide, and assists absorption of the bioactive polypeptide into digestive organs when it is orally taken; a fusion polypeptide comprising the polypeptide absorbable into digestive... | 03/22/2011 |
| 7883711 | Use of polypeptides having antimicrobial activity The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for ... | 02/08/2011 |
| 7794732 | Anthrax compositions and methods of use and production Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or... | 09/14/2010 |
| 7749517 | Anthrax antitoxins The present invention provides compositions useful in preparing and/or serving as antitoxins against Bacillus anthracis, the causative agent of anthrax. The present invention also provides polypeptides and polynucleotides relating to the capillary morphogenis... | 07/06/2010 |
| 7731979 | Protective antigen having fluorinated histidine residues The unnatural amino acid analogue 2-fluorohistidine (2-FHis) was incorporated into protective antigen to produce a protein which resists protonation at physiological pH by reducing the side-chain pKa. The protein structure was unperturbed by the incorporation of flu... | 06/08/2010 |
| 7544363 | Topical compositions containing extracellular products and uses thereof The present invention discloses compositions derived from an isolated Bacillus species spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for to... | 06/09/2009 |
| 7541042 | Topical compositions containing extracellular products and uses thereof The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for t... | 06/02/2009 |
| 7537771 | Expression system An immunogenic reagent which produces an immune response which is protective against Bacillus anthracis, said reagent comprising one or more polypeptides which together represent up to three domains of the full length Protective Antigen (PA) of B. anthraci... | 05/26/2009 |
| 7491404 | Acellular immunogenic compositions and acellular vaccine compositions against The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis ... | 02/17/2009 |
| 7435418 | Receptor for toxin The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotid... | 10/14/2008 |
| 7393647 | Methods for detecting infection This invention pertains to methods for detecting B. anthracis and antibodies to B. anthracis, the causative agent of anthrax, in a subject. ... | 07/01/2008 |
| 7374888 | Methods for detecting infection This invention pertains to methods for detecting B. anthracis and antibodies to B. anthracis, the causative agent of anthrax, in a subject. ... | 05/20/2008 |
| 7329738 | Assays for detection of This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthr... | 02/12/2008 |
| 7323179 | Methods and compositions for the treatment and prevention of and other bacterial infections The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis... | 01/29/2008 |
| 7319028 | Process for producing sporangia of , control agent, and controlling method The present invention provides a process for efficiently producing sporangia of Bacillus popilliae containing spores and parasporal bodies having controlling effects on Scarabaeidae insects, and a control agent and controlling method for Scarabaeida... | 01/15/2008 |
| 7285289 | Nanoparticle vaccines The present invention relates to nanoparticle vaccines comprised of a carrier, particularly polymerized lipids, having multiple copies of an antigen or combinations of different antigens displayed on the carrier. Such antigen-displaying nanoparticles may also displa... | 10/23/2007 |
| 7282580 | Protein molecule useful for inhibition of anthrax toxin The present invention relates to a novel molecule useful for anthrax toxin inhibition in vivo and also provides a method for in vivo inhibition of anthrax toxin action using the new molecule. ... | 10/16/2007 |
| 7264815 | Process for producing a recombinant protein in a mycobacterium host plasmid pJAM2 This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the ... | 09/04/2007 |
| 7261900 | Recombinant modified protective antigen for use in vaccines The invention relates to improved methods of producing and recovering sporulation-deficient B. anthracis mutant stains, and for producing and recovering recombinant B. anthracis protective antigen (PA), especially modified PA which is protease resistan... | 08/28/2007 |
| 7232569 | Type III secretion pathway in , and uses therefor Disclosed is a newly identified and characterized type III secretion system in Aeromonas salmonicida. The invention also encompasses the use of components of the novel secretion system in immunoprotection against A. salmonicida infection, as well as ot... | 06/19/2007 |
| 7201912 | Recombinant immunogenic compositions and methods for protecting against lethal infections from Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis having a variant of recombinant Bacillus anthracis protective antigen (rPA) and a variant of recombinant Bacillus anthracis lethal ... | 04/10/2007 |
| 7176275 | Anthrax and small pox replikins and methods of use Isolated peptides of the Bacillus anthracis Anthrax Toxin Lethal factor Protein pX01–107, antibodies specific for the peptides and methods of stimulating the immune response of a subject to produce antibodies to the Bacillus anthracis Anthrax Toxin L... | 02/13/2007 |
| 7115725 | Multi-mutant diphtheria toxin vaccines Disclosed is DNA encoding diphtheria toxin polypeptides having multiple mutations, which render the polypeptides useful as vaccines. ... | 10/03/2006 |
| 7115269 | Attenuated strain used as a vehicle for oral immunization The present invention is directed to an attenuated Salmonella comprising a eukaryotic expression vector for delivery of the eukaryotic expression vector to a eukaryotic cell. Delivery may be to eukaryotic cells cultured in vitro or to cells in vivo, such as b... | 10/03/2006 |
| 7074913 | Receptor for toxin The present invention relates to mammalian anthrax toxin receptor polypeptides and polynucleotides encoding same as well as related polypeptides and polynucleotides, vectors containing the polynucleotides and polypeptides, host cells containing related polynucleotid... | 07/11/2006 |
| 7037503 | Compounds and methods for the treatment and prevention of bacterial infection The invention provides mutant forms of pore-forming toxins. These mutant toxins may be used in vaccines for the prevention of bacterial infection. Additionally, dominant negative mutants may be administered as therapeutics for the treatment of bacterial infection. | 05/02/2006 |
| 6994997 | Gram positive bacteria deprived of HtrA protease activity and their uses The invention concerns bacteria strains, obtained from gram-positive bacteria whereof the genome size is not more than 3.2 Mb, and wherein the HtrA surface protease is inactive. Said strains are useful for expressing exported proteins of interest. ... | 02/07/2006 |
| 6979449 | Acellular immunogenic compositions and acellular vaccine compositions against The invention concerns an acellular immunogenic or vaccine composition for producing antibodies against Bacillus anthracis comprising a protective antigen (PA) and killed and optionally purified spores, obtained from mutating strains of Bacillus anthracis ... | 12/27/2005 |
| 6962705 | Hybrid Bacillus thuringiensis δ-endotoxins with novel broad-spectrum insecticidal activity Disclosed are novel synthetically modified B. thuringiensis chimeric crystal proteins having improved insecticidal activity against coleopteran, dipteran and lepidopteran insects. Also disclosed are the nucleic acid segments encoding these novel peptides. Met... | 11/08/2005 |
| 6939703 | Amylolytic enzymes derived from the B.licheniformis α-amylase, having improved characteristics The present invention relates to novel amylolytic enzymes having improved characteristics for the use in starch degradation, in textile or paper desizing and in household detergent compositions. The disclosed α-amylases show surprisingly improved properties with re... | 09/06/2005 |
| 6916474 | Antibodies with increased affinities for anthrax antigens The invention overcomes the deficiencies of the prior art by providing antibody compositions having improved affinities for Bacillus anthracis antigens. The compositions have important thereapeutic and diagnostic applications, including treatment or detection... | 07/12/2005 |
| 6913756 | Monoclonal antibodies specific for anthrax and peptides derived from the antibodies thereof The present invention provides monoclonal antibodies which are highly specific for Bacillus spores. Also provided are peptides derived from those monoclonal antibodies. Both the antibodies and peptides are highly specific and can discriminate between spores of poten... | 07/05/2005 |
| 6905692 | Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof The present invention discloses compositions derived from an isolated Bacillus species, spores, or an extracellular product of Bacillus coagulans comprising a supernatant or filtrate of a culture of said Bacillus coagulans strain, suitable for t... | 06/14/2005 |
| 6875435 | In vivo CTL elicitation by heat shock protein fusion proteins maps to a discrete domain and is CD4+ T cell-independent The present invention relates to a method of inducing a CD8+ CTL response to a molecule in an individual deficient in CD4+ T cells comprising administering to the individual an hsp or a portion of an ATP binding domain of an hsp joined to the m... | 04/05/2005 |
| 6828110 | Assays for detection of Bacillus anthracis This invention provides novel methods, reagents, and kits that are useful for detecting B. anthracis. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of B. anthr... | 12/07/2004 |
| 6752992 | Toxins active against pests The subject invention concerns materials and methods useful in the control of non-mammalian pests and, particularly, plant pests. In a specific embodiment, the subject invention provides new Bacillus thuringiensis toxins useful for the control of lepidopteran... | 06/22/2004 |
| 6733751 | Use of Emu Oil and its various fractions as a carrier for antifungal, antibacterial, and antiviral medications & preparations An animal-derived lipid is disclosed that is useful as a carrying agent for anti-microbial formulations. Pharmaceutical and other preparations including Emu Oil are also described as profoundly useful components in anti-bacterial, anti-fungal, and anti-viral treatme... | 05/11/2004 |
